Adecatumumab

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

Adecatumumab (Anti-Human EPCAM Recombinant Antibody; MT201) 是 IgG1 同型的全人单克隆抗体，靶向人 EpCAM。Adecatumumab 在几乎所有腺癌中都有表达，其活性与 K-Ras 状态无关。

Adecatumumab (Anti-Human EPCAM Recombinant Antibody; MT201) is a full human monoclonal antibody of the IgG1 isotype, targeting human EpCAM. Adecatumumab is expressed in almost all adenocarcinomas, and its activity is not dependent of K-Ras status.

Adecatumumab (4 μM; 18 h) shows diverse kinetic binding activities among human Adecatumumab and murine Adecatumumab in B16/EpCAM 3E3 cells.Adecatumumab (0.1 ng/mL-0.1 mg/mL; 4 h) shows a dose-dependent Antibodies depend on cell-mediated cytotoxicity (ADCC) activity in natural killing (NK) cells.

Adecatumumab (300 μg/mouse; i.v. bolus injection; 3 times per week) inhibits tumor growth in B16/EpCAM xenograft tumor model in mice, both of human adecatumumab and mu-adecatumumab.Both human adecatumumab and mu-adecatumumab (300 μg/mouse; i.v. bolus injection; single dose) exhibit a bi-exponential curve progression of serum concentration with an early distribution phase between 0 and 10 h and a terminal elimination phase.Animal Model:Female immunocompetent C57BL/6 mice (6-10 weeks old) with B16/EpCAM (i.v.)Dosage:250 μg/mouse and 600 μg/mouse for human Adecatumumab; 125 μg/mouse and 300 μg/mouse for murine Adecatumumab Administration:250 μg/mouse and 600 μg/mouse for human Adecatumumab; 125 μg/mouse and 300 μg/mouse for murine Adecatumumab Result:Both of them exhibited anti-tumor activity against B16/EpCAM cells in mice.Although human adecatumumab inhibited the size of tumor colonies mice, the number of colonies was only slightly reduced after treatment without significant difference.In contrast, mu-adecatumumab induced a highly significant reduction in the number of lung tumor colonies by >85%, and the few remaining tumor colonies were of very small size.

——

Others

Other Targets

Others

——

——

503605-66-1

——

>98% (HPLC)

——

——

——

(-20℃)

With Ice Pack

≥ 2 years